EmtinB as treatment for neurodegenerative dementia and Alzheimer’s disease Source: NeuroScientific Biopharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022
  • The company today has submitted an application for an early-phase clinical trial involving EmtinB for Human Research Ethics Committee (HREC) approval
  • The timeline for approval is expected to be on par with NSB’s plans to begin its clinical trial in June
  • With the HREC review process underway, NeuroScientific says it has officially transitioned from being a preclinical to a clinical-stage company
  • NeuroScientific Biopharmaceuticals last traded at 22 cents at 10:32 am AEST

NeuroScientific Biopharmaceuticals (NSB) has reported it is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022.

The company today said it had submitted an application for an early-phase clinical trial involving EmtinB for Human Research Ethics Committee (HREC) approval.

EmtinB is a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma. The drug has been shown to be safe and well-tolerated at high concentrations and is able to penetrate the blood-brain barrier.

The focus of the planned study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans. This can then be used to guide efficacy outcomes during future trials in patients.

The trial will include up to 30 healthy participants and will be undertaken by a leading WA-based clinical research partner, Linear Clinical Research.

The timeline for approval is expected to be on par with NSB’s plans to begin its clinical trial in June.

“Most importantly, the company is one step closer to bringing a much-needed therapeutic option with disease-modifying potential to patients with Alzheimer’s disease and Multiple Sclerosis,” NeuroScientific’s Managing Director and Chief Executive Officer, Matt Liddelow, said.

“With the HREC review process underway and other supporting activities well-advanced, NeuroScientific has officially transitioned from being a preclinical to a clinical-stage company.”

Shares in NeuroScientific Biopharmaceuticals were down 2.27 per cent to 22 cents at 10:32 am AEST

NSB by the numbers
More From The Market Herald

" Provaris Energy (ASX:PV1) signs MoU with Northern Marine for GH2 Carrier development

Provaris Energy (ASX:PV1) has signed a memorandum of understanding (MoU) with UK-based Northern Marine Management, a…
Aguia Resources (ASX:AGR) - Managing Director, Fernando Tallarico

" Aguia Resources (ASX:AGR) receives first results from Andrade

Aguia Resources (ASX:AGR) has received the first results from a 2000-metre diamond drilling program at the…
Chalice Mining (ASX:CHN) - Managing Director, Alex Dorsch

" Chalice Mining (ASX:CHN) eyes $100m for Julimar

ASX 200 minerals explorer Chalice Mining (ASX:CHN) has received firm commitments to raise roughly $100 million.

" QEM (ASX:QEM) commissions pilot plant

QEM (ASX:QEM) has commissioned its vanadium and oil shale pilot plant, with the plant scheduled to…